ClinicalTrials.gg
CompletedNCT00293020Updated Oct 5, 2012Results posted

Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy

A Phase 3 interventional study of BEMA Fentanyl in Pain and Cancer, sponsored by BioDelivery Sciences International. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-05.

Sponsored by BioDelivery Sciences International · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,884 studies in Pain with a site in United States — 314 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.

Enrollment
396th of 2,562
244 · median 66
Started
2006
with 106 others
Phase 3
343 of 2,884
17 open now
Registered
199th of 2,884
by date

Among the 2,884 studies in Pain with a site in United States, this one is the 396th largest by enrollment of the 2,562 interventional ones that give a count, is one of 107 that started in 2006, is one of 343 in phase 3, and was the 199th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

314 of the 2,884 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

309 more — sign in →

All 314 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,884 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of BEMA fentanyl at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy. The standard of care for these breakthrough pain episodes is a rapid onset, short acting analgesic with minimal associated sleepiness. Oral morphine, oxycodone and hydromorphone are routinely used, but because of slow and variable oral absorption, the pain control is not the best with these products. Oral transmucosal fentanyl citrate (OTFC) has been used successfully in treating breakthrough pain episodes associated with cancer. OTFC is a lozenge of fentanyl on a stick and is administered by continuously swabbing the interior of the subject's mouth until the product is dissolved (approximately 15 to 30 minutes). The buccal route of administration avoids the delay and variability associated with oral absorption.

BioDelivery Sciences International, Inc. (BDSI) has developed BEMA (BioErodible MucoAdhesive) fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small disc that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the disc readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the disc are water soluble, so the entire dosage form dissolves within 30 minutes of application.

03

Conditions studied

  • Pain
  • Cancer

Keywords

  • Breakthrough Pain in Cancer Patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant and non-lactating female. A female of is eligible to participate in this study if she is using an acceptable method of .
  • 18 years or older
  • Patient must have pain associated with cancer or cancer treatment
  • Patient must be on a stable current regimen of oral opioids equivalent to 60 - 1000 mg/day of oral morphine or 50 - 300 µg/hr of transdermal fentanyl (e.g. oxycodone 30 mg, methadone 20 mg, and hydromorphone 7.5 mg)
  • Regularly experience 1 - 4 breakthrough pain episodes per day that require additional opioids for pain control
  • At least partial relief of breakthrough pain by use of opioid therapy
  • Subject must be able to self-administer the study medication correctly.
  • Subject must be willing and able to complete the electronic diary card with each pain episode.
  • Signed consent must be obtained at screening prior to any procedures being performed.

Exclusion criteria

Exclusion Criteria:

  • Psychiatric/cognitive or neurological impairment that would limit the subject's ability to understand or complete the diary
  • Cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of respiratory depression
  • Recent history or current evidence of alcohol or other drug substance (licit or illicit) abuse
  • Rapidly escalating pain that the investigator believes may require an increase in the dosage of background pain medication during the study
  • Moderate (Grade 3) to severe (Grade 4) mucositis (subjects with less than moderate mucositis are permitted and must be instructed to not apply the BEMA disc at a site of inflammation)
  • Strontium 89 therapy within the previous 6 months
  • Any other therapy prior to the study that the investigator considers could alter pain or the response to pain medication.
  • Use of an drug within 4 weeks preceding this study • History of or intolerance to fentanyl
  • Regularly more than 4 episodes per day
  • performance status of 4 or 5
  • Subject is pregnant, actively trying to become pregnant, breast feeding or not using adequate measures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    1

    BEMA Fentanyl

    Drug: BEMA Fentanyl

Interventions

  • buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily

    Also known as: bioerodible mucoadhesive system

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events.

    After the first dose of BEMA Fentanyl, all adverse events were recorded and summarized.

    Time frame: Participants were followed for the duration of the study, an average of 126 days

07

Results

Posted Oct 5, 2012

Participant flow

The enrollment period was 3/14/06 - 6/13/08. Subjects were recruited from academic \& private clinics in the US. Two groups of subjects were eligible for enrollment in this study. Subjects were eligible to enter this study following completion of the placebo-controlled study, FEN-201 or they were enrolled directly into this study.

Participant flow — Overall Study
MilestoneOpen Label Fentanyl Treatment
Started244
Completed82
Not completed162
Withdrew: Withdrawal by subject34
Withdrew: Adverse event30
Withdrew: Death32
Withdrew: Lack of efficacy12
Withdrew: Lost to follow-up4
Withdrew: Protocol violation6
Withdrew: Physician decision21
Withdrew: Other reason22
Withdrew: No dose taken1

Outcome measures

PrimaryPercentage of Participants With Adverse Events.

After the first dose of BEMA Fentanyl, all adverse events were recorded and summarized.

Time frame:
Participants were followed for the duration of the study, an average of 126 days
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events.
percentage of participantsOpen Label Fentanyl Treatment
Percentage of Participants With Adverse Events.88.5

Adverse events

Collected over The duration of a subject's particpation in the trial.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label Fentanyl Treatment—121/243 (49.8%)215/243 (88.5%)
Most frequent serious events
Showing 10 of 109
Most frequent serious events
EventOpen Label Fentanyl Treatment
Disease progressionGeneral disorders27/243
PneumoniaInfections and infestations17/243
Deep vein thrombosisVascular disorders6/243
SepsisInfections and infestations5/243
anemiaBlood and lymphatic system disorders3/243
DysphagiaGastrointestinal disorders3/243
CellulitisInfections and infestations3/243
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/243
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/243
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/243
Most frequent other events
Showing 10 of 33
Most frequent other events
EventOpen Label Fentanyl Treatment
NauseaGastrointestinal disorders74/243
VomitingGastrointestinal disorders52/243
DizzinessNervous system disorders35/243
AnemiaBlood and lymphatic system disorders31/243
Edema peripheralGeneral disorders29/243
DehydrationMetabolism and nutrition disorders29/243
Disease progressionGeneral disorders28/243
DyspneaRespiratory, thoracic and mediastinal disorders28/243
ConstipationGastrointestinal disorders26/243
AstheniaGeneral disorders25/243

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Open Label Fentanyl Treatment
<=18 years0
Between 18 and 65 years168
>=65 years75
Age Continuous
Age Continuous(years)Open Label Fentanyl Treatment
Mean58.0 ± 12.12
Sex: Female, Male
Sex: Female, Male(Participants)Open Label Fentanyl Treatment
Female128
Male115
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open Label Fentanyl Treatment
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American23
White209
More than one race0
Unknown or Not Reported9
Region of Enrollment
Region of Enrollment(participants)Open Label Fentanyl Treatment
United States243
08

Study locations

1 site
  • ResearchPoint
    Austin, Texas 78746, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2006
First posted
Feb 17, 2006
Start
Feb 2006
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Oct 5, 2012
Last update
Oct 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00293020
Lead sponsor
BioDelivery Sciences International
Responsible party
Sponsor
First posted
Feb 17, 2006
Start date
Feb 2006
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Oct 5, 2012
Last update
Oct 5, 2012

Study contacts

David Blum, MD
study chair · BioDelivery Sciences International

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fentanyl Buccal Soluble Film

Start the discussion